TORONTO, Feb. 23 /CNW/ - Transition Therapeutics Inc. ("Transition")
(TSX: TTH) announced that a presentation of positive preclinical data with
Alzheimer's disease lead product AZD-103 was made at the Keystone Symposia on
Alzheimer's Disease held in Breckenridge, Colorado. A series of preclinical
studies in a widely accepted animal model of Alzheimer's disease showed that
AZD-103 can prevent and reduce disease effects including the formation of
amyloid beta fibrils, impaired cognitive function and accelerated mortality.
These outcomes occurred regardless of whether AZD-103 was administered before
the onset of disease or during the symptomatic phase of disease indicating
AZD-103's potential as a preventative and therapeutic agent for Alzheimer's
disease.
